Conestoga Capital Defends Iradimed Despite Stock Decline

Conestoga Capital Advisors highlighted Iradimed Corporation in its second-quarter 2026 investor letter, noting that the medical device company detracted from the firm's strategy performance during the period. Iradimed reported another quarter of double-digit revenue growth, but its stock price declined as investors focused on the rollout pace of the new 3870 pump.

Iradimed management indicated that the replacement cycle for the 3870 platform is expected to build gradually over several quarters. Despite the short-term market reaction, Conestoga Capital Advisors expressed continued confidence in the early demand for the platform and believes the replacement opportunity will support durable long-term growth for the company.